Gefurulimab Maintains Myasthenia Gravis Benefits Through 1 Year

(MedPage Today) -- Investigational gefurulimab, a dual-binding nanobody that blocks complement component 5 (C5) activation, sustained functional improvements for 1 year in people with generalized myasthenia gravis, data from the open-label extension...